Acceleron is developing its lead product candidate, luspatercept, in a strategic global partnership with Celgene Corporation, the industry leader in hematology. Discovered by Acceleron, luspatercept is currently being evaluated in multiple Phase 2 and Phase 3 trials to treat the chronic, sometimes debilitating anemias associated with myelodyspastic syndromes (MDS) and beta-thalassemia. It is the first novel approach for generating red blood cells to enter pivotal studies in more than 20 years, with potential to vastly improve many patients’ lives by reducing or eliminating the need for frequent and lifelong blood transfusions. The program is fully funded by Celgene, enabling Acceleron to invest in furthering its other therapeutic programs. In addition, we are also partnered with Celgene to develop sotatercept, which is being evaluated in multiple Phase 2 investigator-sponsored trials for myelofibrosis and other indications.
Acceleron is also collaborating with Adimab, an innovator in antibody discovery and optimization. Adimab is working to identify fully human antibodies that Acceleron may develop and commercialize. We are funding the research and have the option to exclusively license newly discovered antibodies.
Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s remarkable capacity for cellular growth and repair.
We would welcome discussions on meaningful strategic collaborations. You can reach us at BD@acceleronpharma.com.